Company Overview - Revvity has a market capitalization of $13.86 billion with an earnings yield of 4.4%, which is favorable compared to the industry's 3.7% [1] - The company delivered an earnings surprise of 13.3% in the last reported quarter [1] FDA Approval and Product Development - Revvity received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone, making it the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma [2] - The assay is processed on Revvity's random-access iSYS or i10 instruments, offering quick turnaround times, high-throughput testing, minimal technician training, and high accuracy [4] - The assay is expected to enhance diagnostic capabilities for conditions like hypogonadism and impotence by providing direct measurement of free testosterone levels in a single test [4] - Management believes the FDA clearance will expand the FDA-cleared menu for EUROIMMUN's ChLIA automation solutions, serving a diverse patient pool across all demographics [5] - Results on EUROIMMUN's ChLIA platforms are expected to be rapidly available, with the first result available in 48 minutes and an estimated throughput of nearly 60 tests per hour [15] Market and Industry Prospects - The global testosterone test market was valued at $100 million in 2023 and is anticipated to reach $208.1 million by 2034, growing at a CAGR of 6.9% [6] - Factors driving the market include rising awareness about hormonal disorders and increasing prevalence of male infertility [6] - The latest FDA clearance is expected to be a significant milestone for Revvity, boosting its business in this growing market [6] Recent Developments - In November 2024, Revvity expanded its collaboration with Genomics England to advance critical genomic initiatives across the UK [7] - The company reported solid revenue growth in its third-quarter 2024 results, both on a reported and organic basis [7] Stock Performance - Following the FDA approval announcement, Revvity's shares lost nearly 2.2% by Friday's closing [3] - Historically, the company has gained a top-line boost from regulatory achievements and product launches, but the stock declined overall despite the latest FDA approval [3] - Over the past year, Revvity's shares have gained 2.8%, outperforming the industry's 9.8% decline, while the S&P 500 gained 23% [9] Comparison with Industry Peers - Cardinal Health (CAH) has a Zacks Rank 2 (Buy) with an estimated long-term growth rate of 10.5% and an average earnings surprise of 11.2% over the trailing four quarters [11] - ResMed (RMD) has a Zacks Rank 2 with an estimated long-term growth rate of 14.8% and an average earnings surprise of 6.4% over the trailing four quarters [12] - Boston Scientific (BSX) has a Zacks Rank 2 with an estimated long-term growth rate of 13.8% and an average earnings surprise of 8.3% over the trailing four quarters [12] - Cardinal Health's shares have gained 14.9% compared to the industry's 2.1% growth, ResMed has gained 34.5% compared to the industry's 7.8% growth, and Boston Scientific has rallied 58.3% compared to the industry's 7.8% growth over the past year [11][12][13]

Revvity, Inc. (NYSE: RVTY ) is clearly a leader in life sciences and diagnostics. Both of these revenue verticals provide cutting-edge tools and platforms for drug discovery and development, as well as early detection of genetic and infectious conditions. The company has a globalMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, U ...

It has been about a month since the last earnings report for Revvity (RVTY) . Shares have lost about 8.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Revvity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. RVTY Q3 Earnings & Revenues Beat Estimates, Guidance R ...

Table of Contents Title of each class Trading Symbol (s) Name of each exchange on which registered Common stock, $1 par value per share RVTY The New York Stock Exchange 1.875% Notes due 2026 RVTY 26 The New York Stock Exchange UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri ...

Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.The company posted quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.13 per share. The company reported quarterly sales of $684.05 million which beat the analyst consensus estimate of $679.65 million.Revvity also authorized a new $1 billion share repurchase program.“We performed well during the third quarter with a return to positive revenue growth, strong margins, and another period of exce ...

Revvity, Inc. (RVTY) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.GAAP EPS from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP EPS in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.Revenue DetailsBased in Waltham, MA, this leading MedTech company repor ...

Revitty Incorporated (NYSE:RVTY) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt ...

Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.27%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.13 per share when it actually produced earnings of $1.22, delivering a surprise of 7.96%.Over the last four quarter ...

Third Quarter 2024 Earnings November 4, 2024 Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "bel ...

FOR IMMEDIATE RELEASE November 4, 2024 Revvity Announces Financial Results for the Third Quarter of 2024 • Revenue of $684 million; 2% reported growth; 2% organic growth • GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 • Raises full year 2024 adjusted EPS guidance • Authorizes new $1 billion share repurchase program • To host Investor Day on November 21st WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Co ...